Nextbiomedical Co (XKRX:389650) ROCE % : 0.00% (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Nextbiomedical Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nextbiomedical Co's annualized ROCE % for the quarter that ended in Dec. 2023 was 0.00%.

Nextbiomedical Co ROCE % Historical Data

The historical data trend for Nextbiomedical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nextbiomedical Co ROCE % Chart

Nextbiomedical Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

-294.27

-38.59

Nextbiomedical Co Quarterly Data
	Dec20	Dec21	Dec22	Dec23
ROCE %	-	-1,177.07	-154.35	-

Nextbiomedical Co ROCE % Calculation

Nextbiomedical Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-6947.145	/	( ( (32135.74 - 30968.05)	+	(29643.392 - 33785.662) )	/ 2 )
	=	-6947.145	/	( (1167.69	+	-4142.27)	/ 2 )
	=	-6947.145	/	-1487.29
	=	467.10 %

Nextbiomedical Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Dec. 2022 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Dec. 2022 )		(Q: Dec. 2023 )
	=	-27788.58	/	( ( (32135.74 - 30968.05)	+	(29643.392 - 33785.662) )	/ 2 )
	=	-27788.58	/	( ( 1167.69	+	-4142.27 )	/ 2 )
	=	-27788.58	/	-1487.29
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Nextbiomedical Co (XKRX:389650) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Nextbiomedical Co ROCE % Related Terms

Thank you for viewing the detailed overview of Nextbiomedical Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nextbiomedical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nextbiomedical Co Ltd (XKRX:389650) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Venture-ro, No. 6, 100 beongil, Yeonsu-gu, Incheon, KOR

Website

https://www.nextbiomedical.co.kr/kr

Nextbiomedical Co Ltd is an bio-solution company. The company develops and commercializes therapeutic agents for treating diseases based on polymer and drug delivery system technology. The company has developed products that include endoscopic hemostatic agents, vascular embolic microspheres, and others.

Nextbiomedical Co Headlines

No Headlines